Valneva shares rebound 3.5% and move back above their 20-period moving average (MM20)

A rebound that brings the stock back above its MM20

Shares of Valneva gain 3.47% to €2.57 intraday, while the SBF 120 advances 1.47%. The price sits 3.05% above its MM20 (€2.49), but remains 3.90% below its MM50 (€2.67) and 11.52% below its MM200 (€2.90).

The rebound comes amid a 3.59% gain over the week, while the stock is still down 34.14% over one year.

The RSI at 51 is neutral. The MACD, still negative, sees its histogram return to positive territory, a sign that selling pressure is easing. Support stands at €2.33, and resistance at €2.79.

In the same sector, Sanofi rises 1.73%. In contrast to this rebound, the stock had fallen 2% on November 2 before regaining 3% the previous day.

A cautious half-year report and an anticipated Lyme disease file

When it published its H1 2026 results on August 13, Valneva confirmed its outlook for 2026, despite the persistent negative impact of the geopolitical context on travel. Among the risks cited was the company's dependence on deliveries of IXIARO to the U.S. Department of Defense, whose timing is uncertain.

On the opportunity side, the company pointed to regulatory decisions expected within the next twelve months on its candidate vaccine against Lyme disease. The company also saw its authorization of Ixchiq revoked in the United Kingdom in early October.

The stock, which trades on Euronext Paris and on the Nasdaq in the form of ADSs, shows a 17.44% gain over three months. Resistance at €2.79 is the closest level above the current price.